Cabazitaxel rtd 505(b)(2?

Question

Accepted Answer

Cabazitaxel and the 505(b)(2) Pathway

Item	Details
Drug	Cabazitaxel (brand name Jevtana)
Approved Indication	Hormone‑refractory metastatic prostate cancer (used in combination with prednisone)
Regulatory Pathway	Original NDA was filed under Section 505(b)(1) (traditional “new drug” application) and approved by the FDA in May 2010.
505(b)(2) Status	No 505(b)(2) application has been filed for cabazitaxel (neither for a new formulation, route of administration, dose strength, or indication). The FDA has no 505(b)(2) approval for this product.

Why 505(b)(2) Was Not Used

Data Source
- Cabazitaxel is a novel taxane; its pre‑clinical and clinical data were entirely generated by the sponsor.
- A 505(b)(2) application is typically chosen when a sponsor can rely on existing data from an FDA‑approved product or from the literature. Since no such data were available, the traditional 505(b)(1) route was required.
Complex Chemistry
- The active moiety (cabazitaxel) is a small, synthetic molecule that is not identical to any existing approved drug. This reduces the likelihood that the FDA would accept substantial data from other products.
Commercial Strategy
- The sponsor (Bristol‑Myers Squibb, later Pfizer) was launching the first taxane for prostate cancer. A full NDA gives the sponsor greater control over the data, labeling, and marketing exclusivity.
- A 505(b)(2) could have limited the sponsor’s ability to claim exclusivity or to differentiate the product in the marketplace.

Element	Typical 505(b)(2) Content
New Data	Safety and efficacy data from a clinical trial conducted by the sponsor (often a pivotal study).
Referenced Data	Data from an FDA‑approved drug or from the literature that supports safety, efficacy, or pharmacokinetics.
Advantages	Shorter development time, reduced cost, ability to leverage existing data.
Disadvantages	Lower exclusivity (the referenced product remains available), potential regulatory uncertainty, and limited ability to claim full safety/efficacy profile.

Because cabazitaxel was a first‑in‑class agent with no precedent data to borrow, the 505(b)(1) route was the only viable option.

Cabazitaxel (Jevtana) received FDA approval via a 505(b)(1) NDA, not a 505(b)(2).
If you’re looking for a 505(b)(2) application for a new formulation, dose, or indication of cabazitaxel, you’d have to file a new NDA (505(b)(1)) or a BLA if you’re a biologics‑related approach, because cabazitaxel is a small‑molecule chemotherapeutic.

If you have a specific question about a potential 505(b)(2) filing (e.g., a generic or reformulation), feel free to let me know!